Unknown

Dataset Information

0

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.


ABSTRACT: Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy in double-transgenic mice expressing PSA and HLA-DRB1*1501 (DR2bxPSA F1 mice). We assessed the capacity of 2 mCMV-based vectors to induce PSA-specific CD8 T-cell responses and affect the growth of PSA-expressing Transgenic Adenocarcinoma of the Mouse Prostate tumors (TRAMP-PSA). In the absence of tumor challenge, immunization with mCMV vectors expressing either a H2-D(b)-restricted epitope PSA(65-73) (mCMV/PSA(65-73)) or the full-length gene for PSA (mCMV/PSA(FL)) induced comparable levels of CD8 T-cell responses that increased (inflated) with time. Upon challenge with TRAMP-PSA tumor cells, animals immunized with mCMV/PSA(65-73) had delay of tumor growth and increased PSA-specific CD8 T-cell responses, whereas animals immunized with mCMV/PSA(FL) showed progressive tumor growth and no increase in number of splenic PSA(65-73)-specific T cells. The data show that a prototype CMV-based prostate cancer vaccine can induce an effective antitumor immune response in a "humanized" double-transgenic mouse model. The observation that mCMV/PSA(FL) is not effective against TRAMP-PSA is consistent with our previous findings that HLA-DRB1*1501-restricted immune responses to PSA are associated with suppression of effective CD8 T-cell responses to TRAMP-PSA tumors.

SUBMITTER: Klyushnenkova EN 

PROVIDER: S-EPMC3366429 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova Elena N EN   Kouiavskaia Diana V DV   Parkins Christopher J CJ   Caposio Patrizia P   Botto Sara S   Alexander Richard B RB   Jarvis Michael A MA  

Journal of immunotherapy (Hagerstown, Md. : 1997) 20120601 5


Cytomegalovirus (CMV) is a highly immunogenic virus that results in a persistent, life-long infection in the host typically with no ill effects. Certain unique features of CMV, including its capacity to actively replicate in the presence of strong host CMV-specific immunity, may give CMV an advantage compared with other virus-based vaccine delivery platforms. In the present study, we tested the utility of mouse CMV (mCMV)-based vaccines expressing human prostate-specific antigen (PSA) for prosta  ...[more]

Similar Datasets

| S-EPMC5672794 | biostudies-literature
| S-EPMC6798091 | biostudies-literature
| S-EPMC3816976 | biostudies-literature
| S-EPMC3939483 | biostudies-literature
| S-EPMC8218728 | biostudies-literature
| S-EPMC3466379 | biostudies-literature
| S-EPMC3153429 | biostudies-literature
| S-EPMC1641801 | biostudies-literature
| S-EPMC6905002 | biostudies-literature
| S-EPMC3662661 | biostudies-literature